{"nctId":"NCT02359890","briefTitle":"SMART-SF Radiofrequency Ablation Safety Study","startDateStruct":{"date":"2015-03-01","type":"ACTUAL"},"conditions":["Atrial Fibrillation"],"count":165,"armGroups":[{"label":"Treatment Group","type":"EXPERIMENTAL","interventionNames":["Device: THERMOCOOL速 SMARTTOUCH速 (RF ablation treatment)"]}],"interventions":[{"name":"THERMOCOOL速 SMARTTOUCH速 (RF ablation treatment)","otherNames":["Pulmonary vein isolation"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptomatic paroxysmal atrial fibrillation (AF) who have had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment and a physician's note indicating recurrent, self-terminating AF. Electrocardiographic documentation may include, but is not limited to, electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip\n* Failed at least one antiarrhythmic drug (AAD) (class I or III, or atrioventricular (AV) nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced by recurrent symptomatic AF, or intolerable to the AAD\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause\n* Previous surgical or catheter ablation for atrial fibrillation\n* Amiodarone at any time during the past 3 months\n* Any percutaneous coronary intervention (PCI), cardiac surgery, or valvular cardiac surgical or percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) within the past 2 months\n* Any carotid stenting or endarterectomy\n* Coronary artery bypass graft (CABG) surgery within the past 6 months\n* AF episodes lasting \\>7 days\n* Documented left atrial (LA) thrombus on imaging\n* LA size \\>50 mm\n* Left ventricular ejection fraction (LVEF) \\< 40%\n* Contraindication to anticoagulation (heparin or warfarin)\n* History of blood clotting or bleeding abnormalities\n* MI within the past 2 months\n* Documented thromboembolic event (including transient ischemic attack (TIA)) within the past 12 months\n* Rheumatic Heart Disease\n* Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV\n* Awaiting cardiac transplantation or other cardiac surgery within the next 12 months\n* Unstable angina\n* Acute illness or active systemic infection or sepsis\n* Diagnosed atrial myxoma\n* Presence of implanted implantable cardioverter defibrillator (ICD)\n* Significant pulmonary disease, (eg, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study\n* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)\n* Enrollment in an investigational study evaluating another device, biologic, or drug\n* Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter\n* Presence of a condition that precludes vascular access\n* Life expectancy or other disease processes likely to limit survival to less than 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Early Onset Primary Adverse Events","description":"Early onset is defined as within 7 days of the atrial fibrillation (AF) ablation procedure. Primary adverse events (AE) include Death, Myocardial infarction (MI), Pulmonary vein (PV) stenosis, Diaphragmatic paralysis, Atrio-esophageal fistula, Transient Ischemic Attack (TIA), Stroke / Cerebrovascular accident (CVA), Thromboembolism, Pericarditis, Cardiac Tamponade / Perforation, Pneumothorax, Major Vascular Access Complications / Bleeding, Pulmonary edema (Respiratory Insufficiency), and Heart block.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Non-Primary Serious Adverse Events (SAEs)","description":"This secondary safety endpoint includes non-primary serious adverse events (SAEs) within 7 days post-procedure and serious adverse events from 8 days to 30 days post-procedure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Acute Success","description":"Acute success is defined as confirmation of entrance block in all Pulmonary veins (PV).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Effectiveness Endpoint: Freedom From Documented Atrial Fibrillation (AF)/Atrial Tachycardia (AT)/Atrial Flutter (AFL)","description":"The freedom from documented AF/AT/AFL based on electrocardiographic data","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":159},"commonTop":["Fatigue","Atrial Flutter","Groin hematoma","Radiating chest pain","Shortness of breath"]}}}